×
0 0 0 0 0 0.0137005649717514 0.0169491525423729 0.00875706214689272
Stockreport

Argenx receives €2.6M VLAIO grant to explore new applications of ABDEG technology [Seeking Alpha]

ARGENX SE ADS (ARGX)  More Company Research Source: Seeking Alpha
PDF Argenx (NASDAQ: ARGX ) has received a €2.6M grant from the Flanders Innovation and Entrepreneurship (VLAIO) agency. The grant will be used to explore new applications and modes of action of Argenx’s proprietary ABDEG technology, the Fc engineering technology used in the design of efgartigimod (ARGX-113) to augment the clearance of disease-causing autoantibodies. The €2.6M subsidy was granted to Argenx through its Innovative Access Program to fund new research around the proprietary ABDEG technology. Click to subscribe to real-time analytics on ARGX Now read: Principia Biopharma Begins U.S. IPO Effort » Subscribe for full text news in your inbox [Read more]

IMPACT SNAPSHOT EVENT TIME: ARGX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
ARGX alerts

from News Quantified
Opt-in for
ARGX alerts

from News Quantified